益赛普致不良反应统计分析  

Statistical Analysis for Adverse Reactions Induced by Etanercept

作　　者：刘娟[1] 朱灿辉[2] 

机构地区：[1]广东省中医院药学部,广东广州510120 [2]广东省中医院脑病二科,广东广州510120

出　　处：《临床医学工程》2012年第12期2258-2259,共2页Clinical Medicine & Engineering

摘　　要：目的了解生物制剂益赛普致不良反应(ADR)发生的特点与相关因素。方法检索《中国期刊全文数据库》2004至2012年收录的有关生物制剂致ADR的文献,筛选出符合卫生部ADR诊断标准的文献共46篇,共1347例患者,并进行分类、统计与分析。结果益赛普ADR发生率约为14%(189例/1347例),临床表现以皮肤局部反应为主要症状的ADR发生率最高,有116例(占8.6%),上呼吸道感染、发热次之,有41例(占3.1%)。结论临床上使用注射益赛普时,应注意做好给药前相关化验检查,并加强对ADR的监测,及时对症处理,确保此药的使用安全。Objective To realize the characteristics and related factors of adverse reactions which were caused by etanercept. Methods We searched ＂CNKI Full-Text Database＂ （2004-2012） including the etanercept-induced ADR literature, selected and statistically analyzed 46 essays, 1 347 patients in line with the diagnostic criteria for ADR of the Ministry of Health. Results Etanercept ADR rate was about 14% （189/1 347）. The clinical performance of skin local reaction as the main symptoms, and it had the highest rate of ADR, with 116 cases （8.6%）; the second was infection of the upper respiratory tract, fever, 41 cases （3.1%）. Conclusions As clinical application of etaner cept has higher incidence of ADR, we should pay attention to relevant tests before administration, and strengthen the monitoring of ADR, with timely symptomatic treatment to ensure drug safety.

关 键 词：益赛普 药品不良反应 合理用药 

分 类 号：R969.3[医药卫生—药理学]